Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 9/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119110 | 0.90 | BDKRB1 (0.40) | BDKRB1LMNADGAT1 | |
| SCHEMBL5119414 | 0.89 | BDKRB1 (0.51) | BDKRB1LMNA | |
| SCHEMBL6763252 | 0.88 | BDKRB1 (0.54) | BDKRB1LMNA | |
| SCHEMBL5126334 | 0.88 | BDKRB1 (0.40) | BDKRB1LMNADGAT1 | |
| SCHEMBL5119727 | 0.88 | BDKRB1 (0.38) | BDKRB1LMNA | |
| SCHEMBL5118850 | 0.86 | LMNA (0.42) | BDKRB1LMNA | |
| SCHEMBL5117876 | 0.86 | BDKRB1 (0.38) | BDKRB1LMNADGAT1 | |
| SCHEMBL5126495 | 0.86 | BDKRB1 (0.38) | BDKRB1 | |
| SCHEMBL5124690 | 0.85 | LMNA (0.41) | BDKRB1LMNADGAT1 | |
| SCHEMBL5118636 | 0.85 | BDKRB1 (0.41) | BDKRB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | BDKRB1 1217/4885LMNA 4632/4885DGAT1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.